Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541594 | 0.87 | GRIA2 (0.46) | GRIA2PTPRAKDM4ECYP2C19 | |
| SCHEMBL28005090 | 0.87 | GRIA2 (0.46) | GRIA2PTPRAKDM4ECYP2C19 | |
| SCHEMBL3774503 | 0.81 | SCN9A (0.41) | GRIA2PTPRAKDM4E | |
| SCHEMBL15540819 | 0.81 | PPARG (0.47) | GRIA2 | |
| SCHEMBL6762817 | 0.80 | SCN9A (0.47) | — | |
| SCHEMBL3775959 | 0.77 | GRIA2 (0.48) | GRIA2PTPRA | |
| SCHEMBL3775956 | 0.77 | GRIA2 (0.48) | GRIA2PTPRA | |
| SCHEMBL6762820 | 0.73 | GRIA2 (0.50) | GRIA2PTPRACYP2C19 | |
| SCHEMBL2143592 | 0.71 | GRIA2 (0.50) | GRIA2PTPRAKDM4ECYP2C19 | |
| SCHEMBL21061874 | 0.71 | GRIA2 (0.56) | GRIA2PTPRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | GRIA2 46/4885PTPRA 3943/4885KDM4E 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.